Informed Consent for Ketamine Treatment: Essential Elements

Introduction: Informed Consent in the Context of Novel Therapeutics

The informed consent process for ketamine treatment carries heightened significance due to the drug's controlled substance status, off-label prescribing context (for racemic ketamine), novel mechanism of action, and unique side effect profile that includes dissociative experiences. Informed consent for ketamine treatment must go beyond standard pharmaceutical disclosure to address the specific informational needs of patients considering a treatment that produces transient altered states of consciousness, carries abuse potential, and -- in many applications -- lacks the regulatory validation conferred by FDA approval for the specific indication (Sisti et al., 2018).

The ethical foundation of informed consent rests on the principles of autonomy, beneficence, and non-maleficence -- requiring that patients receive adequate information to make voluntary, informed decisions about their care. For ketamine therapy, the informational landscape is complicated by rapidly evolving evidence, substantial media coverage (both optimistic and alarmist), and the patient's potential desperation stemming from treatment-resistant illness. Ensuring that consent is truly informed -- reflecting accurate understanding rather than hopeful projection or fear-based refusal -- requires careful attention to content, communication, and process.

Legal and Ethical Framework

Off-Label Prescribing Disclosure

Racemic ketamine for psychiatric indications constitutes off-label use -- prescribing an FDA-approved medication (approved for anesthesia) for a non-approved indication. While off-label prescribing is legal and common in medicine, it triggers specific informed consent obligations. The American Medical Association guidelines recommend that physicians disclose the off-label nature of the prescription, the evidence supporting the off-label use, and the alternatives that carry on-label approval (AMA, 2019).

For intranasal esketamine (Spravato), the consent discussion is modified by the existence of FDA approval for treatment-resistant depression. However, uses of esketamine outside the approved indication (e.g., for bipolar depression, anxiety disorders, or pain) remain off-label and warrant corresponding disclosure.

Controlled Substance Disclosure

Ketamine's Schedule III classification carries implications that should be disclosed: the drug has recognized abuse potential, there are legal restrictions on its distribution, and patients may face social or occupational consequences related to controlled substance use (insurance implications, drug testing, professional licensing).

Essential Disclosure Elements

Nature of the Treatment

The consent discussion should explain, in accessible language:

• What ketamine is: An anesthetic medication being used at sub-anesthetic doses for its antidepressant/analgesic effects
• How it works: NMDA receptor blockade and enhancement of synaptic plasticity (simplified for lay comprehension)
• Route of administration: Specific to the planned treatment (IV infusion, intranasal spray, oral/sublingual tablet or liquid)
• Treatment setting: Where treatment will occur, who will be present, and what monitoring will be performed
• Treatment timeline: Expected number of sessions, frequency, duration of each session, and anticipated course of treatment

Expected Benefits

• Response rates: Approximately 50-70% of treatment-resistant depression patients show meaningful improvement within 24-72 hours of initial infusion. Remission rates are lower (approximately 25-35%).
• Speed of onset: Hours to days, compared with weeks for conventional antidepressants
• Duration of benefit: Typically one to two weeks following a single infusion; longer with repeated treatments but maintenance therapy may be needed
• Anti-suicidal effects: Rapid reduction in suicidal ideation in many patients (if applicable to the clinical context)
• Limitation of benefit: Not all patients respond, and among responders, not all maintain response long-term. The treatment is not curative.

Risks and Side Effects

Common and Expected Effects

• Dissociative symptoms (60-80%): Altered perception, derealization, depersonalization, feeling "disconnected" from body or surroundings. Typically onset within 10-15 minutes of infusion, peak at 30-40 minutes, resolve within 60-120 minutes.
• Blood pressure elevation (majority): Transient increase of 15-25 mmHg systolic. Monitored throughout treatment and managed pharmacologically if needed.
• Nausea (10-30%): May be prevented or treated with ondansetron.
• Dizziness/lightheadedness (30-50%): Usually resolves within 1-2 hours post-treatment.
• Drowsiness/fatigue: Common in the hours following treatment.
• Headache (approximately 15-25%): Usually mild and self-limiting.

Less Common but Important Risks

• Anxiety or agitation during treatment (5-15%): Some patients find the dissociative experience distressing rather than neutral or positive. Benzodiazepine rescue is available.
• Transient perceptual disturbances: Visual or auditory distortions during acute drug effect.
• Bladder symptoms: With repeated treatment, potential for lower urinary tract symptoms (frequency, urgency). Monitored through regular assessment.
• Liver enzyme elevations: Possible with repeated treatment. Monitored through periodic blood tests.
• Cognitive effects: Transient impairment during and immediately after treatment (no driving for 24 hours). Long-term cognitive effects at therapeutic doses appear minimal based on available evidence but long-term data are limited.

Abuse and Dependence Risk

• Ketamine is a controlled substance with recognized abuse potential
• The treatment will be administered in a supervised setting to mitigate this risk
• Patients should disclose any history of substance use disorders
• Signs of developing dependence or misuse will be monitored
• For take-home formulations: specific risks of unsupervised use and responsibilities of the patient

Alternatives to Ketamine Treatment

The consent process must present available treatment alternatives:

• Other pharmacological options: Augmentation strategies (lithium, atypical antipsychotics), switching antidepressant classes, MAOIs, thyroid hormone augmentation
• Neuromodulation: ECT, rTMS, vagus nerve stimulation
• Psychotherapy: CBT, interpersonal therapy, behavioral activation
• Combined approaches: Pharmacotherapy plus psychotherapy optimization
• Intranasal esketamine (Spravato): If racemic ketamine is being proposed, the FDA-approved esketamine alternative should be discussed as a comparator
• No additional treatment: The expected course of illness without intervention

The Right to Refuse or Withdraw

Patients must understand that consent is voluntary and revocable:

• They may decline ketamine treatment without penalty or loss of access to other care
• They may withdraw consent at any time during the treatment course
• Individual infusions/sessions can be stopped at the patient's request
• The treating clinician will continue to provide appropriate alternative care regardless of the ketamine decision

Communication Best Practices

Health Literacy Considerations

The informed consent discussion should be tailored to the patient's health literacy level. Key strategies include:

• Avoiding jargon; when medical terms are necessary, providing clear definitions
• Using numeric risk communication (percentages, frequencies) rather than vague qualifiers ("rare," "common")
• Employing teach-back methods: asking patients to explain key concepts in their own words to verify comprehension
• Providing written materials that patients can review at home before the first treatment

Managing Therapeutic Desperation

Patients with treatment-resistant depression may be in a state of desperation that compromises the voluntariness of their consent. Clinicians should be attentive to signs that the patient is consenting primarily out of desperation rather than informed deliberation. Strategies to address this include:

• Acknowledging the patient's suffering and hope while maintaining realistic expectations
• Explicitly stating that refusal is acceptable and will not affect the therapeutic relationship
• Providing adequate time for decision-making (not requiring same-day consent)
• Encouraging discussion with family members, other providers, or trusted advisors

Addressing Media-Driven Expectations

Many patients arrive at ketamine consultations with expectations shaped by media coverage that may overstate benefits or understate risks. The consent discussion provides an opportunity to calibrate expectations by presenting evidence-based response rates, acknowledging the limitations of current knowledge, and distinguishing between the controlled clinical trial evidence and individual anecdotal reports.

Special Consent Considerations

Capacity Assessment

In some clinical scenarios -- particularly acute psychiatric presentations with severe depression, cognitive impairment, or suicidal crisis -- the patient's decision-making capacity may be compromised. When capacity is questionable, formal capacity assessment should precede the consent discussion. The four elements of decisional capacity (understanding, appreciation, reasoning, and expressing a choice) provide a framework for evaluation (Appelbaum, 2007).

If a patient lacks capacity, surrogate decision-making via legally authorized representatives (healthcare proxy, guardian) may be invoked, though the involvement of surrogates in psychiatric treatment decisions raises additional ethical complexities.

Minors and Adolescents

For patients under 18, informed consent from a parent or legal guardian is required, supplemented by the minor patient's assent when developmentally appropriate. The consent discussion with parents should emphasize the limited evidence base in pediatric populations, the neurodevelopmental safety uncertainties, and the off-label nature of the treatment. Adolescents should receive age-appropriate explanations and have their questions and concerns addressed directly.

Research Versus Clinical Consent

When ketamine is administered as part of a research protocol, the consent process must meet Institutional Review Board (IRB) standards, which typically exceed clinical informed consent requirements. The distinction between research participation and clinical treatment should be clearly communicated, including the patient's right to withdraw from the research without affecting clinical care.

Documentation Requirements

Elements of the Consent Document

A comprehensive written consent document for ketamine therapy should include:

1. Patient identification and date
2. Diagnosis and indication for treatment
3. Description of the proposed treatment (route, dose, frequency, setting)
4. Off-label status disclosure (for racemic ketamine or non-TRD indications)
5. Expected benefits and realistic response rates
6. Common and serious risks, including dissociation, hemodynamic effects, cognitive effects, abuse potential, and long-term safety uncertainties
7. Available alternative treatments
8. Post-treatment activity restrictions (no driving for 24 hours)
9. Monitoring plan (vital signs, lab tests, cognitive screening)
10. Patient acknowledgment of understanding and voluntary consent
11. Clinician attestation of the informed consent discussion
12. Signatures of patient, witness, and clinician with date

Ongoing Consent

Informed consent for ketamine is not a one-time event but an ongoing process. Significant changes in treatment plan (dose modification, frequency change, route change), new safety information, or evolution of the patient's clinical status should trigger updated consent discussions. Periodic reaffirmation of consent -- particularly at the transition from induction to maintenance therapy -- demonstrates respect for patient autonomy and ensures that consent remains informed and current.

Conclusion

The informed consent process for ketamine treatment must address the unique informational challenges posed by a controlled substance with dissociative properties being used in a predominantly off-label context for treatment-resistant conditions. Essential elements include disclosure of the off-label status, realistic presentation of benefits and risks, discussion of alternatives, and attention to factors that may compromise voluntary decision-making -- including therapeutic desperation and media-driven expectations. Comprehensive documentation, health literacy-appropriate communication, and ongoing consent throughout the treatment course provide the foundation for ethical and legally defensible ketamine prescribing practice.

References

• PubMed: Mapping Consent Practices for Outpatient Psychiatric Use of Ketamine — Analysis of informed consent documents from 23 outpatient ketamine clinics identifying gaps in disclosure practices
• PubMed: A Consensus Statement on the Use of Ketamine in Treatment of Mood Disorders — APA task force consensus on ketamine clinical use including informed consent and patient safety recommendations
• FDA MedWatch: Safety Information and Adverse Event Reporting — FDA safety reporting system for monitoring and reporting ketamine-related adverse events
• MedlinePlus: Esketamine Nasal Spray Drug Information — National Library of Medicine prescribing information for Spravato including REMS-mandated consent requirements